Vebreltinib: PTPRZ1-MET fusion high-grade gliomaA matched targeted option for recurrent glioma,
seeking more survival time with a specific fusion.
After glioma recurrence, confirmed PTPRZ1-MET fusion and eligible pathology may allow treatment with the matched oral targeted drug vebreltinib. In FUGEN, median overall survival was 6.3 months versus 3.4 months with chemotherapy, but results from a small sample cannot predict an individual's lifespan.
Free initial service consultation · Understand your options and budget before you travel
- Median overall survival
- Vebreltinib 6.3 months; chemotherapy 3.4 months
- Median progression-free survival
- 1.9 months versus 1.1 months
Open-label randomised study with a relatively small sample. Medians do not predict individual lifespan or mean everyone gains the same time. View the evidence
Only for specific adult gliomas with PTPRZ1-MET fusion. The price is a reference from Hunan's proposed 2025 procurement listing, not an international patient quote; fully self-funded, without insurance or free-drug deductions. View sources
Turn a fusion test result into a specific treatment pathway
Chinese teams progressed from discovering the fusion target to drug development and a randomised study, providing a matched drug for this specific recurrent glioma. Treatment planning still requires joint assessment by neuropathology, molecular testing and neuro-oncology specialists.
Identify the fusion that matches the medicine
PTPRZ1-MET fusion differs from MET amplification or positive protein expression. Review the original test and pathology to assess the match.
Plan anticancer treatment alongside daily care
Consider surgery and radiotherapy history and neurological function when discussing oral medication, local treatment and supportive care, including brain imaging follow-up and symptom management.
Budget for continued oral treatment and neurological care
Include medication, brain reassessment and necessary supportive treatment together. Estimate for fully self-funded foreign patients without Chinese health insurance or free drugs. Hunan's proposed 2025 listing price is only a reference for enquiries.
- Hunan publication, 2025
- 100mg × 60 capsules: RMB 8,010 per pack
- Calculated drug cost for 30 days
- At the study dose of 300mg twice daily, 180 capsules = RMB 24,030
- Diagnosis and monitoring
- Pathology review, fusion testing, contrast-enhanced MRI and biochemistry priced separately
- Supportive treatment
- Antiseizure treatment, cerebral oedema management and necessary admission require hospital pricing
A proposed listing price is not a confirmed international patient quote. Continued treatment depends on benefit and tolerance; transport, accommodation and caregiver costs are additional.
Finding treatment that fits you
starts with the reports you already have.
Clarifying your disease type and previous treatment helps establish whether this option could form part of a plan for you.
- Genetic requirementsPTPRZ1-MET fusion confirmed by reliable testing; a report merely stating a MET abnormality is insufficient.
- Approved pathology scopePreviously treated adults after treatment failure with WHO grade 4 IDH-mutant astrocytoma, or glioblastoma with a history of lower-grade glioma.
- Ability to tolerate treatmentAssess consciousness, swallowing, performance status and liver and kidney function. Rapidly worsening symptoms require urgent care first.
How long might treatment help, and what are its limits?
FUGEN compared vebreltinib with temozolomide or cisplatin plus etoposide in a full analysis set of 81 patients. The full paper was published in 2026. Overall disease control remains limited, and study medians cannot predict individual survival.
- Study population
- Previously treated high-grade glioma with PTPRZ1-MET fusion
- Hazard ratio for death
- HR 0.52; 95% CI 0.32–0.85; open-label randomised study, full analysis set of 81, a relatively small sample
- Median progression-free survival
- 1.9 months versus 1.1 months
- Drug risks
- Rash, peripheral oedema and liver toxicity; monitoring and appropriate adjustments are needed
Overall disease control remains limited. Small subgroup results cannot be generalised to all gliomas, and treatment cannot be promised to replace every local option.
You do not need to book flights first.
Clarify treatment and costs before you travel.
Tell us your diagnosis, previous treatments and main concerns. We help you communicate about Shanghai consultation requirements, budgets and travel arrangements.
- Bring initial and recurrence pathology, IDH results and slides available for review to confirm eligible pathology
- Provide the complete PTPRZ1-MET fusion report to avoid treating other MET abnormalities as the same target
- Organise original contrast-enhanced MRI images and surgery and radiotherapy records to assess recurrence and local treatment needs
- List chemotherapy, steroids, antiseizure medicines and neurological changes to coordinate medication and supportive care
Start the first conversation with the records you already have.
You do not need to arrange new tests yourself for an initial consultation.
Get answers to the questions that matter to you
before you travel.
Costs, potential benefit and further treatment deserve specific answers before departure.
Can I use this regimen if my report shows only MET amplification?
It cannot be directly applied. This page requires PTPRZ1-MET fusion plus the relevant adult pathology and prior-treatment criteria. Amplification or positive protein expression cannot substitute for a fusion result.
How do I arrange medication before travelling to China?
Confirm the accepting department, pharmacy supply and fully self-funded international patient quote before travel. Approval does not mean every hospital can prescribe it, and a proposed listing price is not a confirmed quote.
How often is reassessment needed, and what requires immediate attention?
Treatment usually continues until progression or intolerance, with regular MRI at intervals determined by the doctor. Seek prompt medical care for altered consciousness, severe headache or seizures.
Connect your test reports to specific treatment and care arrangements.
Starting with your condition and budget, we help communicate about consultations and treatment arrangements in Shanghai.
The initial service consultation is free; the treating doctor assesses your specific medical plan.
Sources and image credits
Information is compiled from public approval documents, studies and prices and does not replace an individual medical assessment. Research and cost figures each have a defined scope; published prices are not personal international patient quotes. Costs are discussed on a self-funded basis without Chinese health insurance or free-drug assistance.
- Apollomics official announcement: vebreltinib approval for specific PTPRZ1-MET fusion glioma · 2024-04-25
- Beijing Tiantan Hospital: Jiang Tao team's fusion target discovery and vebreltinib development · Verified 2026-10-03
- Bao et al.: full phase III randomised controlled FUGEN paper · 2026-03-11
- Hunan Healthcare Security Administration: proposed listing price for vebreltinib 100mg × 60 capsules · 2025-01; verified 2026-10-03
- Company submission published by the National Healthcare Security Administration: vebreltinib prescribing safety information · 2025; verified 2026-10-03